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Abstract
Despite recent advances in chronic heart failure (HF) therapy, the prognosis of HF patients remains poor, with high rates of
HF rehospitalizations and death in the early months after discharge. This emphasizes the need for incorporating novel HF
drugs, beyond the current approach (that of modulating the neurohumoral response). Recently, new antidiabetic oral medications (sodium-glucose cotransporter 2 inhibitors (SGLT2i)) have been shown to improve prognosis in diabetic patients
with previous cardiovascular (CV) events or high CV risk profile. Data from DAPA-HF study showed that dapaglifozin is
associated with a significant reduction in mortality and HF hospitalization as compared with placebo regardless of diabetes
status. Recently, results from EMPEROR-Reduced HF trial were consistent with DAPA-HF trial findings, showing significant
beneficial effect associated with empagliflozin use in a high-risk HF population with markedly reduced ejection fraction.
Results from the HF with preserved ejection fraction trials using these same agents are eagerly awaited. This review summarizes the evidence for the use of gliflozins in HF treatment.
Keywords Chronic heart failure · Diabetes mellitus · Gliflozin · Empagliflozin · Dapagliflozin · Canagliflozin · Sodiumglucose cotransporter 2 inhibitors (SGLT2i)
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Introduction
Heart failure (HF) is one of the major public health problems
and causes of high rates of morbidity and mortality worldwide. Type 2 diabetes mellitus (T2DM) is a highly prevalent
disease with more than 400 million people affected [1]. The
relative risk of incident HF and/or idiopathic cardiomyopathy
is higher in patients with diabetes compared with those without diabetes [2–6]. Moreover, impaired glucose regulation
is associated with a high risk of development of HF [7, 8].
Reducing mortality and hospitalizations is the most
important clinical endpoint in HF patients, and the risk
of these events is markedly increased in HF patients with
concomitant diabetes: the higher mortality risk attributable to diabetes is applicable to both HF with preserved
ejection fraction (HFpEF) and with reduced ejection fraction (HFrEF), as well as to ischemic and non-ischemic
cardiomyopathy.
The pathophysiologic mechanisms connecting T2DM
and HF are complex and cannot be explained by the sharing of some CV risk factors alone such as hypertension
and coronary artery disease (CAD). Direct toxic effects of
hyperglycaemia, effects of renin–angiotensin–aldosterone
system (RAAS) activation, mitochondrial dysfunction, and
metabolic derangements in cardiac myocytes, for example,
are some of the mechanisms that play key roles in the development of HF in diabetic patients [9–11].
Inhibitors of the sodium-glucose cotransporter 2
(SGLT2i), also called gliflozins, are a new class of blood
glucose lowering medications that block renal glucose reabsorption in the proximal tubule, leading to increased urinary
sodium and glucose excretion. The aim of this review is
to introduce this new class of antidiabetic drugs, describe
preclinical and clinical evidence in support of their use, and
emphasize their role in the treatment of HF by providing
practical advice for their use by non-diabetologists.

Mechanism of action
The proximal renal tubule absorbs most of the filtered glucose which is about 180 g/day. This is achieved by utilizing active N
 a + absorption through basolateral N
 a +/K +
ATPase pumps in the epithelial tubular cells that generate

Table 1  SGLT2 inhibitors in
T2DM and CVD according the
ESC recommendations
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an electrochemical gradient favouring glucose to enter the
cell using the sodium-glucose cotransporter1 (SGLT) and
SGLT2 when the N
 a+ concentration in the glomerular filtrate
is higher versus lower N
 a+ concentration in the epithelial
cells [12]. SGLT2 is a high-capacity, low-affinity transporter
that is expressed almost exclusively in the initial portion
of the proximal tubule [13], which accounts for 90% of
the reabsorbed glucose. Residual glucose is reabsorbed by
SLGT1, a low-capacity, high-affinity transporter, at the end
of the proximal tubule. Patients with T2DM express a significantly higher number of SGLT2s in the proximal tubule
as compared with healthy individuals [14]. Consequently,
glucose reabsorption from the glomerular filtrate is greatly
increased in T2DM patients. The glucose resorption capacity from the blood reaches its maximum when the blood
glucose levels exceed 200 mg/dl, at which point it would be
excreted in urine to prevent extreme hyperglycemia. Inhibition of SGLT2 lowers this threshold [15]. In patients with
T2DM in treatment with SGLT2i, lower incidence of hypoglycaemia was noted, because SGLT2i leave the metabolic
counter regulation intact. In fact, SGLT2i increase plasma
glucagon concentrations and gluconeogenesis in patients
with T2DM [16]. Furthermore, SGLT2 inhibition enhances
lipolysis and shifts substrate utilisation from carbohydrates
to lipids [17], contributing to a reduction in fat mass and
body weight [18]. This physiological response to excessive
renal glucose excretion may prevent hypoglycaemia. Since
SGLT2i utilize glomerular filtration rate, its glucose lowering ability declines when the eGFR falls < 45 ml/min/1.73
m2. In addition, in patients without hyperglycemia, it has
been observed that the glycosuria with SGLT2i is reduced,
resulting in lower risk of hypoglycemia (Table 1) [25].

Pleiotropic effects
The use of SGLT2i is associated with many favourable
effects such as reduction of preload (diuretic effects [19])
and afterload (blood pressure (BP) [20], arterial stiffness
[21], improvement of mitochondrial efficiency [22], delay
of decline in eGFR, delay of microalbuminuria and macroalbuminuria, weight loss [23], reduction in epicardial adipose tissue [24], improvement in glycaemia, and reduction
in uric acid [25]. Considering those effects and numerous

Recommendations
SGLT2 inhibitors
Empagliflozin, canagliflozin, or dapagliflozin are recommended in patients with T2DM
and CVD, or at very high/high CV risk, to reduce CV events
Empagliflozin is recommended in patients with T2DM and CVD to reduce CV events

Class

Level

I

A

I

B
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hypotheses has been formulated to justify the cardioprotective effects of gliflozins:
1. The diuretic hypothesis [26]: increase natriuresis and
act as diuretics leading to a reduction in preload and
myocardial stretch);
2. The blood pressure lowering hypothesis [27]: decrease
blood pressure and afterload;
3. The ‘thrifty substrate’ hypothesis [28]: favor the production of ketones, which can act as a ‘superfuel’ in the
cardiac and renal tissue;
4. The metabolic hypothesis [29]: improve/change metabolic variables;
5. The anti-inflammatory hypothesis: cause many antiinflammatory effects [30];
6. The RAAS hypothesis [31]: through the angiotensin II
type II receptors in the context of simultaneous RAAS
blockade may lead to vasodilation and positive inotropic
effects;
7. The sodium hypothesis [32]: directly decrease the activity of the Na+-H+exchanger in myocardial cells leading to restoration of mitochondrial calcium handling in
cardiomyocytes;
8. The SGLT1 inhibition hypothesis [33] (some SGLT2
inhibitors also exhibit SGLT1 inhibitory action possibly resulting in an attenuation of oxidative stress in the
ischemic myocardium).
Of note, it has been widely demonstrated that SGLT2i
have diuretic and natriuretic effect (combining properties
of proximal tubule diuretics and osmotic diuretics) [34].
Because SGLT2 reabsorbs sodium along with glucose, use
of SGLT2i increase urinary sodium excretion and reduce
plasma volume, resulting in haematocrit increase and blood
pressure lowering as reported in the EMPA-REG Outcome
study [35] and the Canvas program [36, 37]. The SGLT2i
reno-protective effect is also demonstrated by the reduction of albuminuria and macroalbuminuria; these could be
explained by increased sodium delivery at the macula densa
and subsequent activation of tubuloglomerular feedback,
which increases afferent arteriolar tone and may reduce
intraglomerular pressure [38].
Additionally, as compared with classical diuretics,
SGLT2i may have differential effects on interstitial and intravascular compartment, as recently proposed. In this regard,
findings from healthy volunteers showed that dapaglifozin
is associated with a reduction in sodium and interstitial fluid
with negligible change in blood volume as opposed to loop
diuretic bumetanide, which showed greater reductions in
intravascular volume; dapaglifozin administration induce
greater electrolyte-free water clearance, and greater fluid
clearance from the interstitial fluid space than from the circulation via peripheral sequestration of osmotically inactive

sodium. This may also limit the deleterious effects of reflex
neurohumoral stimulation that usually occurs in response
to intravascular volume depletion with traditional diuretics.
Other, recently, demonstrated that beneficial effects of
SGLT2i are directly or indirectly related to a hemodynamic
effect due to SGLT2 influence on RAAS system include the
improvement in left atrial dilatation, attenuated intracardiac
fibrosis, improved dp/dt of left ventricle [39]. SGLT2i produce mild but meaningful reductions in BP [40]-36 and a
strict BP control in patients with diabetes is associated with
reductions in cardiovascular and renal risk.

Preclinical evidences in heart failure
In several preclinical models of T2DM, SGLT2i improved
endothelial function and arterial stiffness [37], decreased
oxidative stress [37], exerted anti-inflammatory effects
[37], ameliorated cardiac fibrosis [37], and improved LV
systolic [37] and diastolic function [37]. Dapagliflozin may
be able to prevent and reduce cardiac fibrosis after MI, also
in non diabetic patients, by activating the STAT3 signalling
pathway promoting M2 macrophage activation and, consequently, reducing the myofibroblast infiltration and collagen
accumulation [35]. Empagliflozin improved cardiac function
and reduced myocardial fibrosis in non-diabetic rats with
HFrEF after a large MI [36]. These effects are probably
related to Empagliflozin action on metabolism of cardiac
cells. It may be able to reduce mitochondrial DNA damage
and oxidative stress, stimulating mitochondrial biogenesis
and increasing ATP levels [37]. In a rabbit model, Empagliflozin exerted a direct effect on cardiomyocytes, inhibiting
the Na+/K+ exchanger, with a reduction of N
 a+ and C
 a++
intracellular concentrations and an increase of mitochondrial
Ca++ [38]. Empagliflozin influences the activity of C
 a++/
calmodulin-dependent Kinase II in myocytes that is overexpressed in HF ventricle [38], it ameliorates adverse cardiac
remodelling and HF by influencing the switches of myocardial fuel utilization away from glucose toward ketone bodies, free fatty acid, and branched-chain amino acid; improving myocardial energetics; enhancing left ventricular (LV)
systolic function; and ameliorating LV reverse remodelling
[39]. On the basis of this pathophysiological background, the
clinical usefulness of SGLT2i has been evaluated in humans
with HF with or without DM.

Gliflozin in diabetic patients: clinical trials
results
Four gliflozins have been approved by the US Food and Drug
Administration (FDA) for glycaemic control in T2DM. The
EMPA-REG OUTCOME trial [40] was the first long-term
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CV safety trial performed in 7020 patients with a long duration of T2DM (57% > 10 years), at high CV risk (CV disease
in 99%), who were randomized to empaglifozin 10 or 25 mg
once daily or placebo, in addition to standard of care. The
primary major adverse CV events (MACE) endpoint (CV
death, non-fatal myocardial infarction, or non-fatal stroke)
was reduced by 14% in the treatment-group compared with
the placebo-group. This reduction was driven mainly by a
highly significant (38%) reduction in CV death. In a secondary analysis, empagliflozin was associated with a 35% reduction in HF hospitalization. The reduction of overall mortality
was 32%. Empagliflozin reduced the endpoint of “new onset
or worsening nephropathy” as well [40].
The CANVAS Program integrated data from two trials
[41, 42] involving a total of 10,142 patients with T2DM
(glycated haemoglobin level ≥ 7.0% and ≤ 10.5%) and
eGFR ≥ 30 ml/min/1.73 m2, in secondary (66%) and primary
prevention (34%) of CV disease, canagliflozin significantly
reduced the primary endpoint by 14% and HF hospitalization by 33%, but the effects on CV death and overall death,
non-fatal myocardial infarction, and non-fatal stroke were
not significant. The comparison among participants with and
without a history of CV disease showed a significant benefit
in secondary prevention.
The DECLARE-TIMI 58 trial [43] examined the effect of
10 mg dapagliflozin o.d. vs. placebo in 6971 patients with DM
and CV disease, and 10,189 patients with DM and multiple CV
risk factors, who were followed for a median of 4.2 years. In
the two primary efficacy analyses, dapagliflozin did not result
in a lower rate of MACE but did result in a lower rate of the
composite endpoint of CV death or hospitalization for HF.
This was driven by a lower rate of hospitalization for HF. Also,
renal endpoints (40% decreases in eGFR to 60 ml/min/m2 and
ESRD or renal death) were significantly reduced by 47%.
A meta-analysis of the three trials including 34,322
patients suggested consistent benefits on reducing the composite of HF hospitalization or CV death, as well as on the
progression of kidney disease, regardless of existing atherosclerotic CV disease or a history of HF [44].
The results of VERTIS-CV trial [45] indicated that ertugliflozin is superior to placebo for reducing CV events in patients
with T2DM and established CVD (23.7% patients with history of HF). Ertugliflozin significantly reduced HF hospitalization. The benefit was consistent regardless of ertugliflozin
dose, history of HF, and systolic function. Total and recurrent
HF events were also reduced in the ertugliflozin arm.

Clinical evidences in heart failure trials
The effects of empagliflozin were analysed in EMPERORReduced [46] in HFrEF patients with and without T2DM. In
this study were enrolled ≈3600 patients with LVEF ≤ 40% and
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patients were randomized to placebo or empagliflozin 10 mg
daily, on top of recommended HF treatment: primary endpoint
was the time-to-first event analysis of the combined risk of
CV death and hospitalization for HF. These trials also evaluated the effects of empagliflozin on renal function, CV death,
all-cause mortality, and recurrent hospitalization events. The
results from EMPEROR-Reduced trial showed that in patients
with HFrEF, the empagliflozin group had a lower risk of CV
death or hospitalization for HF as compared to the placebo
group, regardless of the presence or absence of diabetes [47]
In a randomized, double-blind, placebo-controlled study in
patients with acute decompensated HF (EMPA-RESPONSEAHF study) [48], no difference was observed in dyspnoea,
diuretic response, length of hospital stay, or change in NTproBNP between empagliflozin and placebo. However, a
reduction of the combined endpoint of in-hospital worsening HF, rehospitalization for HF, or death at 60 days was
observed in the empagliflozin group as compared to placebo.
Empagliflozin treatment was safe, well tolerated, and without
adverse effects on blood pressure or renal function in patients
with acute decompensated HF [48].
Results from DAPA-HF trial [49] demonstrated a significant reduction in CV death, HF hospitalization, and worsening HF or CV death [41] in patients treated with dapagliflozin compared with the placebo group, in both diabetics
and nondiabetics. Dapagliflozin was added to recommend
HFrEF therapy [50] and demonstrated incremental efficacy
and safety in HFrEF patients with and without diabetes.
Dapagliflozin did not strengthen the actions of diuretics in
DAPA-HF [51], and its benefit was similar in patients with
or without ischemic cardiomyopathy or in patients who were
and who were not taking sacubitril/valsartan [52]. Dapagliflozin improved symptoms, physical function, and quality of
life in patients with HFrEF [53]. In a recent post hoc analysis
[54], the benefit of dapagliflozin remained consistent regardless of background HF therapy. The benefit and safety of
dapagliflozin were consistent across the range of SBP [55]
and across the diuretic subgroups [56] examined. Left ventricular EF did not modify the beneficial effect of dapagliflozin in patients with and without diabetes in DAPA-HF
[55]. In the DEFINE-HF [57] in HFrEF patients (EF ≤ 40%,
NYHA class II-III, eGFR ≥ 30 mL/min/1.73 m
 2, and elevated natriuretic peptides (NP)), treatment with dapagliflozin over 12 weeks increase the amount of patients (also without T2DM) with improvements in HF-related health status.
DAPA HF and EMPEROR reduced studied the same
target population, patients with HFrEF (EF < 40%), and
elevated NT proBNP concentration, with or without DM,
but the EMPEROR reduced included preferentially patients
with advanced HFrEF; therefore, the two populations were
overlapping and complementary. The characteristics of the
analysed populations in EMPEROR reduced are illustrated
in Table 2 [46, 47].

Heart Failure Reviews

The primary outcome was the same for DAPA HF and
EMPEROR reduced, and it was a composite outcome of
cardiovascular death or HF. In each trial, the SGLT2 inhibitors reduced significantly the risk of this outcome, but the
benefit was driven mainly by the reduction in HF; the effects
of these drugs on cardiovascular death were modest, particularly in the EMPEROR. This difference in cardiovascular
death could be related to the higher percentage of patients
with advanced HFrEF, but also to a shorter follow-up (16
vs 18 months) and to a higher percent of patients that discontinued therapy in EMPEROR. However, Zannad et al.
[58] have shown in a recent meta-analysis of these two trial
that empaglifozin and dapaglifozin reduced all cause and
cardiovascular death and HF without heterogeneity between
the two trials [59].
Tables 3 and 4 go through trials using gliflozins specifically in HF populations.

Safety of gliflozins
The safety of gliflozins has been under scrutiny given the
reporting of worrisome side effects such as lower limb
amputation, fractures, and genital/urinary infections linked
to increased glycosuria. Increased rates of infections of male
or female genitalia (and less so for urinary infections) were
consistently observed for all three mentioned gliflozins.
Although in the CANVAS Program [42] canagliflozin was
associated with higher rates of fractures (15.4 vs. 11.9 participants with fracture per 1000 patient-years; hazard ratio, 1.26;
95% CI, 1.04 to 1.52), there was significant heterogeneity
between CANVAS and CANVAS-R results [41, 42]; also, in
the CREDENCE trial [59], fracture rates were similar between
the canagliflozin and the placebo groups. A similar risk was
reported in the CANVAS program for lower limb amputation;
no difference as compared to placebo was found neither in
CREDENCE trial [59] nor in the analysis of a large real-world
meta-analysis of 4 databases (OBSERVE-4D) [60]. Such risk
was not documented for both dapaglifozin and empagliflozin.
VERTIS (eValuation of ERTugliflozin effIcacy and Safety
CardioVascular outcomes) trial [61] evaluating a fourth SGLT2
drug—ertugliflozin—showed a similar pattern of adverse effects
with more urinary tract infections (12.1% vs. 10.2%; p < 0.05).
Some patients will experience a decline in eGFR following the initiation of gliflozins. This has been an area of concern, limiting prescription. DAPA-CKD [62] assessed renal
events in a broad range of patients with CKD (including
patients with a low baseline eGFR between 25 and 30 mL/
min per 1.73 m2) with and without DM treated with dapagliflozin. It demonstrated the reduction of risk of kidney
failure, and prolonged survival in people with CKD, with

or without T2DM, independently of the presence of concomitant CV disease.

Actual approach to prescription to SGLT2i
Gliflozins are effective in reducing CV events independent
of their effects on blood glucose, and cardiologists should be
very familiar with how to use them, in order to incorporate
these drugs into the HF therapeutic armamentarium [63]. The
FDA has broadened the labelling of empagliflozin and canagliflozin specifically for use to lower CV risk in patients with
T2DM and established CVD. Despite the potential benefits of
SGLT2i in reducing adverse clinical events, SGLT2i is under
prescribed for eligible patients [63]; furthermore, patients
treated versus those not treated with an SGLT2i were more
likely to be younger and men, and less likely to have prevalent
CAD and HF. In the year after addition of the CV indication
for empagliflozin, endocrinologists contribute to the highest proportion of prescriptions (45.4%), while cardiologists
only to 4.5% of annual prescriptions [64]. The top 3 barriers
for cardiology providers were lack of knowledge about these
medications, concerns of introducing confusion into diabetes
care, and discomfort of prescribing diabetes medications.
The American Diabetes Association and European Association for the Study of Diabetes consensus guidance [65]
provided strong support for upfront CV risk assessment and
consideration of SGLT2 inhibitors as second-line therapies.
Metformin is still preferred as backbone therapy given clinician familiarity, low cost, and widespread availability.
In current HF guidelines, SGLT2i are the first class of
glucose-lowering therapy to prevent HF (in clinical trials and
real-world studies) in patients with T2DM with or without
established CV disease and with or without baseline HF [66].
The European Society of Cardiology (ESC) guidelines
[67] strongly recommend to stratify CV risk in all patients
with T2DM who are antihyperglycemic drug naïve or on
metformin monotherapy and to start SGLT2i in patients with
high or very high risk, irrespective of glycated haemoglobin;
in particular, empagliflozin, canagliflozin, or dapagliflozin
should be used in patients with T2DM and CV disease, or
at very high/high CV risk to reduce CV events and empagliflozin in patients with T2DM and CV disease to reduce
the risk of death.
It is necessary to suggest that cardiologists perform routine measurement of HbA1c in all patients with established
CV disease in order to use a glucose-lowering drug that
improves glycaemia and CV outcome [68].
A few rules may help cardiologists to prescribe SGLT2i.
The former cardiologists should consider thiazide or loop
diuretic dose reduction at the time of SGLT2i initiation to
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Number of patients
Age, years*
Female sex (%)
BMI*
Race, n (%)
White
Black
Asian
Other
Region n. (%)
North America
South America
Europe
Asia Pacific
NHYA class, n (%)
II
III
IV
Heart rate, beats/min*
Systolic blood pressure,
mmHg *
Left ventricular ejection
fraction*
Median NT pro BNP (IQR),
pg/ml
Cause of heart failure, n (%)
Ischemic
Non ischemic
Medical history, n (%)
Hospitalization for heart
failure in < 12 mo
Atrial fibrillation
Diabetes mellitus
Estimated GFR
Mean value, ml/min/1.73
m2

1867
66.5
456 (24.4)
27.8
1304 (69.8)
134 (7.2)
335 (17.9)
94 (5.0)
213 (11.4)
645 (34.5)
677 (36.3)
245 (13.1)
1401 (75.0)
455 (24.4)
11 (0.6)
71.5
121.4
27.2
1926

946 (50.7)
921 (49.3)
574 (30.7)
705 (37.8)
929 (49.8)
62.2

1863
67.2
437 (23.5)
28.0

1325 (71.1)
123 (6.6)
337 (18.1)
78 (4.2)

212 (11.4)
641 (34.4)
676 (36.3)
248 (13.3)

1399 (75.1)
455 (24.4)
9 (0.5)
71.0
122.6

27.7

1887

983 (52.8)
880 (47.2)

577 (31.0)

664 (35.6)
927 (49.8)

61. 8

66.0

916 (38.6)
993 (41.8)

1124 (47.4)

1316(55.5)
857 (36.1)

1428

31.2

1606 (67.7)
747 (31. 5)
20 (0.8)
71.5
122.0

335 (14.1)
401 (16.9)
1094 (46.1)
543 (22.9)

1662 (70.0)
122 (5.1)
552 (23.3)
37 (1.6)

2373
66.2
23.8
28.2

Dapaglifozin

Empaglifozin

Placebo

DAPA-HF

EMPEROR reduced

Table 2  Comparison of the EMPEROR-reduced and DAPA HF populations

65.5

902(38.0)
990 (38.0)

1127 (47.5)

1358 (57.3)
830 (35.0)

1446

30.9

1597 (67.4)
751 (31.7)
23 (1.0)
71.5
121.6

342 (14.4)
416 (17.5)
1060 (44.7)
553 (23.3)

1671 (70.5)
104 (4.4)
564 (23.8)
32 (1.3)

2371
66. 5
23.0
28.1

Placebo
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Laboratory and other
measures (changes from
baseline)***
Glycated haemoglobin %

Death from any cause

Cardiovascular death

Hospitalization for heart
failure

Rate < 60 ml/min/1.73 m2,
n (%)
Device therapy, n (%)
Implantable cardioverterdefibrillator
Cardiac resynchronization
therapy
Heart failure medication,
n (%)
ACE inhibitor or ARB
Sacubitril Valsartan
Beta blockers
Mineralocorticoid receptor
antagonist
Clinical outcomes, n %
Hazard or rate ratio or difference (95% CI)
Primary composite outcome**

Table 2  (continued)

222 (11.9)

1286 (68.9)
387 (20.7)
1768 (94.7)
1355 (72.6)

462 (24.7)

220 (11.8)

1314 (70.5)
340 (18.3)
1765 (94.7)
1306 (70.1)

361 (19.4)
0.75 (0.65–0.86) p < 0.001
246 (13.2)
0.69 (0.59–0.81)
187 (10.0)
0.92 (0.75–1.12)
249 (13.4)
0.92 (0.77–1.10)

− 0.28 ± 1.14

593 (31.8)

578 (31.0)

− 0.12 ± 0.03

266 (14.2)

202 (10.8)

342 (18.3)

906 (48.6)

893 (48.0)

− 0.21 ± 1.14

386 (16.3)
0.75 (0.65–0.85) p < 0.001
237 (10)
0.70 (0.59–0.83)
227 (9.6)
0.82 (0.69–0.98)
276 (11.6)
0.83 (0.71–0.97)

2007 (84.5)
250 (10.5)
2278 (96.0)
1696 (71.59

190 (8.0)

622 (26.2)

962 (40.6)

Dapaglifozin

Empaglifozin

Placebo

DAPA-HF

EMPEROR reduced

− 0.04 ± 1.29

329(13.9)

273(11.5)

326 (13.7)

502 (21.2)

1961 (82.8)
258 (10.9)
2280 (96.2)
1674 (70.6)

164 (6.9)

620 (26.1)

964 (40.7)

Placebo
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*Mean values. **The primary outcome for EMPEROR reduced was a composite outcome of cardiovascular death or hospitalization for heart failure; the primary outcome of DAPA HF was a
composite outcome of worsening heart failure (hospitalization or an urgent visit resulting in intravenous therapy for heart failure) or dead from cardiovascular causes. ***Changes from baseline
at month 8 and from baseline to 52 weeks for EMPEROR reduced

ACE angiotensin converting enzyme, ARB angiotensin receptor blockers, ARNI angiotensin receptor neprilysin inhibitor, BMI body mass index, eGFR estimated glomerular filtration rate,
EMPEROR empaglifozin outcome trial in patients with chronic heart failure, DAPA HF dapaglifozin and prevention of adverse outcomes in heart failure, NHYA New York Heart Association,
NT proBNP N terminal pro B type natriuretic peptide

− 0.19 ± 3.81
101 ± 2944
0.10 ± 4.09
− 0.38 ± 15.27
2.31 ± 3.90
196 ± 2387
− 0.88 ± 3.86
− 1.92 ± 14.92

Dapaglifozin
Placebo

− 0.38 ± 0.10
− 141 (− 784 to 585)
0.08 ± 0.13
1.7 ± 0.4
1.98 ± 0.10
− 244 ± (− 890 to 260)
− 0.73 ± 0.13
− 2.4 ± 0.4

Empaglifozin

Table 2  (continued)

13

Hematocrit
NT proBNP pg/ml
Weight, kg
Systolic blood pressure,
mmHg

DAPA-HF
EMPEROR reduced

Placebo

Heart Failure Reviews

avoid excessive diuresis and volume depletion (SGLT2i may
induce osmotic diuresis via glucosuria); the following suggestions should be given to patients: genital/perineal hygiene
(increased risk of genital infections due to their effect of
increased urinary glucose excretion), regular foot exams
(increased risk of amputation), avoid excessive alcohol.
During multidisciplinary follow-up, serial assessment of
renal function, body weight, blood pressure, and symptoms
(including symptoms of diabetic ketoacidosis) are needed.
In patients with a history of frequent hypoglycemia, recommended medication adjustments include a 50% reduction in
sulfonylurea dose and a 20% reduction in basal insulin dose
at the time of SGLT2i initiation. If the patient is taking a
DPP4i, the prescribing physician may decide to discontinue
that medication before starting the SGLT2i [68–70].

Paradigm shift in HF treatment
RAAS inhibition, beta-blockade, and angiotensin receptor
blockers/neprilysin inhibitors (ARNI) reduce hospitalization and mortality risk in patients with HFrEF; however,
despite these results, HF patients still have an increased risk
for morbidity and mortality and, furthermore, these drugs
often predispose hypotension, renal dysfunction, and electrolyte abnormalities. In recent times, we are witnessing an
important turning point in the treatment of HF; in fact, after
a long time, the interest of cardiologists is shifting from
contrasting the sympathetic system to research new and different targets. In order to improve the development of drug
for HF, the researchers have to develop the “right” drugs,
starting from the “right” targets. Thanks to gliflozins we
are able to begin to know the “Dark Side” of HF beyond
neurohormonal system (new mechanisms and new targets for
drugs in HF). The encouraging results obtained by gliflozins in diabetic patients in terms of prevention of HF events
and in HF patients regardless the presence of diabetes, as in
DAPA-HF trial [71], lead us to imagine a possible role of
gliflozin in the treatment of HFrEF. Because dapagliflozin
was similarly efficacious and safe in patients who were and
who were not taking sacubitril/valsartan in the DAPA-HF
trial [52], the use of both agents together could further low
morbidity and mortality in patients with HFrEF.
Trials with gliflozins as treatment in HFpEF are still ongoing (Table 5). In the next future, there may be some changes in
clinical approach of HF, the management of HF will become
even more multidisciplinary, the diabetologists will be new
allies in the battle against HF, and likely, we could suggest a
diabetologic consultation already in early phase of HF (NYHA
class II) according to baseline characteristics of DAPA-HF [71].
The cardiologist and the other specialists treating patients
with HF may have no difficulties in adopting this class of drugs.
SGLT2i use is not accompanied by hypotension, bradycardia,

Extensively metabolized by glucuronidation (UGT2B7, UGT1A3,
UGT1A8, and UGT1A9), and to a
lesser extent, oxidation to six inactive metabolites

96% of drug is excreted; 54% of drug
in urine (50% is parent drug); 42%
of drug in faeces (most of drug is
parent drug)

Dose adjustment in patients with creatinine clearance < 60 ml/min
Contraindicated or to be stopped
in patients with creatinine Clearance < 45 ml/min/1.73 m2
No adjustment in hepatic failure

Biotransformation

Elimination pathway

Dose modifications

≃1200-fold
5–10 mg once daily
78
1h
12.9 h

Dapagliflozin

≃2200-fold
5–15 mg once daily
70–90%
1h
16 h

Ertuglifozin

Extensive O-glucuronidation
(UGT1A9) to inactive conjugates
(primarily dapagliflozin 3-O- glucuronide)

Extensive O-glucuronidation (UGT1A9
and UGT2B7) to inactive conjugates
(ertugliflozin-2-O-β-glucuronide-M5a;
ertugliflozin-3-O-β-glucuronide-M5c)
CYP-mediated (oxidative) metabolism
is minimal (12%)
96% of drug is excreted; 75% of drug 91.2% of drug is excreted; 50.2% of
84.7% of drug is excreted; 51.7% of
drug in urine (1.5% as parent drug);
in urine (primarily eliminated via
drug in faeces (41.5% parent drug);
40.9% of drug in faeces (33.8% as
urinary excretion, < 2% as parent
33% of drug in urine (< 1% parent
drug); 21% of drug in faeces (15% as parent drug)
drug)
parent drug)
Should not be initiated in patients with Should not be initiated in patients with Should not be initiated in patients with
eGFR < 60 ml/mt/1.73 m2
eGFR < 60 ml/mt/1.73 m2
eGFR < 60 ml/min/1.73 m2
Dose limited to 100 mg once daily
No dose adjustment in patients with
Contraindicated
if eGFR falls to < 60 but > 45 ml/
eGFR > 60 ml/min/1.73 m2
if eGFR < 30 mL/min/1.73 m2
2
min/1.73 m
No dose adjustment in patients with
eGFR > 60 ml/min/1.73 m2
Stopped in patients with
eGFR < 45 ml/min/1.73 m2

≃260-fold
100–300 mg once daily
65
1–2 h
10.6 ± 2.13 h (100 mg)
13.1 ± 3.28 h (300 mg)
Extensively metabolized by O-glucuronidation (UGT1A9 and UGT2B4)
to two major inactive metabolites

Canagliflozin

eGFR estimated glomerular filtration rate, UGTuridine diphosphate-glucuronosyltransferase.

≃2700-fold
10–25 mg once daily
> 60
1.5 h
12.4 h

Selectivity SGLT-2/SGLT-1
Dose range
Oral bioavailability (%)
Tmax
Half-life

Empagliflozin

Table 3  Clinical pharmacology of sodium-glucose co-transporter-2 inhibitors
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Table 4  Comparison of EMPA-REG OUTCOME, CANVAS program, DECLARE-TIMI 58, and VERTIS CV studies
EMPA-REG OUTCOME
(Empagliflozin)
No. patients
Tested dose (s)
Study design

Median study duration
Duration of diabetes

eGFR entry criteria

CANVAS program
(Canagliflozin)

7028 (placebo N = 2333)

10,142 (placebo
N = 4347)
10 or 25 mg once daily
100 or 300 mg once
daily
1:1:1 ratio (100 mg,
1:1:1 ratio (10 mg, 25 mg,
300 mg, placebo)
placebo) with 2 weeks
with 2 weeks singlesingle-blind placebo run-in
blind placebo run-in
period
period
3.1 years
~ 2.41 years
(126.1 weeks)
At least 10 years;
≤ 1 year: 2.7%; > 1 to
average dura5 years: 15.2% > 5 to
tion = 13.5 years
10 years: 25.1% > 10 years:
57.0%
eGFR ≥ 30 ml/min/1.73 m2
eGFR ≥ 30 ml/
(MDRD)
min/1.73 m2

Primary prevention

No

Secondary prevention

Yes (≥ 18-year-old)

Types of patients

All patients with established
CVD: previous MI/unstable angina, known CAD,
previous stroke ( ischemic
or hemorrhagic), occlusive
peripheral artery disease

Primary endpoint (s)

CV death, nonfatal MI, or
nonfatal stroke

VERTIS
CV(Ertuglifozin)

17,160 (placebo N = 8578) 8246 (placebo N = 2747)
10 mg once daily

5 or 15 mg once daily

1:1 ratio (10 mg, placebo)
with 4–8 weeks singleblind placebo run-in
period

1:1:1 ratio (5 mg,
15 mg, placebo)

4.2 years

3.5 years

Median duration ~ 11 years Average duration = 13 years

eGFR ≥ 30 ml/min/1.73
eGFR ≥ 60 ml/min/1.73
m2 (MDRD)
m2 (Cockroft-Gault
equation)
No
35% of patients
59% of patients
(≥ 50-year-old)
(men ≥ 55-year-old,
women ≥ 55-year-old)
65% of patients
41% of patients
Yes (≥ 40 year-old)
(≥ 30-year-old)
(≥ 40-year-old)
Secondary prevenSecondary prevenSecondary Prevention: patients with
tion: established
tion: patients with
established CVD
CVD (ischemic heart
established CVD
(previous MI/
disease, cerebrovascu(previous MI/unstaCABG/PCI; history
lar disease, peripheral
ble angina/ CABG/
of ischemic stroke,
artery disease). Primary
PCI, peripheral
history of carotid
prevention: age +  ≥ 1
revascularizarevascularization;
additional risk factors (
tion; symptomatic
peripheral arterial
(LDL-C > 130 mg/dl, on
with documented
disease (angiographilipid lowering therapy.
hemodynamically
cally documented
BP > 140/90 mm/Hg,
significant carotid or
peripheral vascular
on anti-hypertensive
peripheral vascular
disease, resting ABI
therapy, current tobacco
disease or amputaof < 0.85 plus sympuse)
tion secondary to
toms of claudication;
vascular disease).
amputation, peripheral
Primary Prevention:
bypass, or peripheral
patients with CV
angioplasty of the
risk factors: diabetes
extremities prior to the
duration ≥ 10 years,
Screening visit
SBP > 140 mmHg
on ≥ 1 medication,
current smoker,
micro- or macroalbuminuria, or
HDL-C < 39 mg/dl
MACE (CV death,
a) CV death, MI, or
CV death, nonfatal
nonfatal MI, nonfatal
ischemic stroke
MI, or nonfatal
(MACE); b) CV death or stroke)
stroke
HF hospitalization

Results
Primary endpoint (s)

0.86 (0.74–0.99), P = 0.04

0.86 (0.75–0.97),
P = 0.02

All-cause death

0.68 (0.57–0.82), P < 0.001

0.87 (0.74–1.01)
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DECLARE-TIMI 58
(Dapagliflozin)

(a) 0.93 (0.84–1.03),
P = 0.17 (MACE)
(b) 0.83 (0.73 − 0.95),
P = 0.005
0.93 (0.82 − 1.04)

0.97 (0.85–1.11)

-
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Table 4  (continued)

CV death
HF hospitalization
CV death or HF hospitalization
*Composite renal endpoint

EMPA-REG OUTCOME
(Empagliflozin)

CANVAS program
(Canagliflozin)

DECLARE-TIMI 58
(Dapagliflozin)

VERTIS
CV(Ertuglifozin)

0.62 (0.49–0.77), P < 0.001
0.65 (0.50–0.85), P = 0.002
0.66 (0.55–0.79), P < 0.001
0.54 (0.40–0.75), P < 0.001

0.87 (0.72–1.06)
0.67 (0.52–0.87)
0.78 (0.67–0.91)
0.60 (0.47–0.77)

0.98 (0.82 − 1.17)
0.73 (0.61 − 0.88)
- (see primary endpoint)
0.76 (0.67–0.87)

0.92 (0.77–1.11)
0.70 (0.54–0.90)
0.88 (0.75–1.03)
0.81 (0.63–1.04)

CVD cardiovascular disease, CAD coronary artery disease, MDRD Modification of Diet in Renal Disease criteria, CV cardiovascular, MI myocardial infarction, MACE major adverse cardiovascular events, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoproteincholesterol, SBP systolic blood pressure, CABG coronary artery bypass graft, PCI percutaneous coronary intervention, ABI ankle/brachial-index.
*Composite renal endpoint definitions across studies: (a) EMPAREG: Doubling of serum creatinine level accompanied by eGFR of ≤ 45 ml/
min/1.73 m2, initiation of renal-replacement therapy, or death from renal disease; (b) CANVAS: sustained 40% reduction in eGFR, the need for
renal-replacement therapy, or death from renal causes; (c) DECLARE-TIMI: sustained decrease of 40% or more in eGFR by calculated by means
of the Chronic Kidney Disease Epidemiology Collaboration equation to less than 60 ml per minute per 1.73 m
 2 of body-surface area, new endstage renal disease, or death from renal or cardiovascular causes; (d)VERTIS CV: Renal death, renal replacement therapy, doubling of serum
creatinine.

or hyperkalaemia, which are often the side effects of currently
recommended HF medications. Furthermore, no titration of the
drug is necessary. The cardiologists will learn side effects and
contraindications of gliflozins (for example, increased risk of
genital infections, increased risk of amputation) easily.

Future research and future possible use
Ongoing clinical trials aim to evaluate the impact of gliflozins on circulatory hemodynamics (filling pressures, cardiac output—such as the EMBRACE trial) or LV structure
and function (as assessed by echocardiography or cardiac

magnetic resonance imaging). In order to determine whether
empagliflozin improves cardiac function in non-diabetic
HF patients, EMPA-TROPISM clinical trial [71], a randomized, double-blind, placebo-controlled, will enrol 80
HFrEF patients. The changes in LV end-diastolic volume,
change in peak VO2, and change in LV mass, in LVEF, in
left atrium volumes, in RV function and volumes, in interstitial myocardial fibrosis, and in epicardial adipose tissue,
will be evaluated.
The Empire HF trial [72] (a randomized, double-blinded,
placebo-controlled, including patients with HFrEF) will
clarify the effects and mechanisms of empagliflozin in
HFrEF patients with and without T2DM.

Table 5  Active clinical trials recruiting or not, using gliflozins in HFpEF
Trial name

Trial design: population and primary objective

ClinicalTrials.
gov Identifier:

EMBRACE-HF

• HFr/pEF (ischemic or non-ischemic aetiology) who already have a
CardioMEMs device;
• assess hemodynamic parameters (pulmonary artery diastolic pressure)
• Chronic HFpEF
• Time to first event of adjudicated CV death or adjudicated HHF
• Chronic HFpEF
• Change from baseline in NTproBNP at 6 and 12 weeks
• Chronic HFpEF
• CV death and HF events
• HFpEF
• Change from baseline in 6 min walking distance
• HFpEF and T2DM
• Time to first hospitalization for HF

NCT03030222

EMPEROR-Preserved
PRESERVED-HF
DELIVER
DETERMINE- Preserved
Effect of dapagliflozin plus low dose pioglitazone on
hospitalization rate in patients with HF and HFpEF

NCT03057951
NCT03030235
NCT03619213
NCT03877224
NCT03794518

HF heart failure, EF ejection fraction, HFpEF HF with preserved ejection fraction, EMBRACE-HF Empagliflozin Impact on Hemodynamics in
Patients With Heart Failure, EMPEROR Preserved EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction, PRESERVED-HF Dapagliflozin in PRESERVED Ejection Fraction Heart Failure, DELIVER Dapagliflozin Evaluation to Improve
the LIVEs of Patients With PReserved Ejection Fraction Heart Failure, DETERMINE Preserved Dapagliflozin Effect on Exercise Capacity
Using a 6-min Walk Test in Patients With Heart Failure With Preserved Ejection Fraction, Effect of dapagliflozin plus low dose pioglitazone on
hospitalization rate in patients with HF and HFpEF
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Table 6  Active clinical trials recruiting or not, using empagliflozin in HF
Trial name

Trial design: population and primary objective

ClinicalTrials.gov Identifier:

EMBRACE-HF

• HFr/pEF (ischemic or non-ischemic aetiology) who already
have a CardioMEMs device;
• Assess hemodynamic parameters (pulmonary artery diastolic pressure)
• Acute HF
• Assess change in cardiac output
• HF NYHA II and III, EF < 50%
• End-systolic volume (ESV) is the volume of blood in a ventricle at the end of contraction of the left ventricle (LV)
• Acute decompensated HF
• Total urinary output (UOP) as measured by daily volume
summed up over 5 days
• Chronic HF
• Change from baseline to week 12 in PCr/ATP ratio in the
resting state measured by 31P MRS
• Chronic HF
• Assess changes in total and tissue sodium content
• Chronic HFpEF
• Time to first event of adjudicated CV death or adjudicated
HHF
• Chronic HF
• PVCs percentage of all beats in a pre-specified period captured on ICD or CRTD/P device
• HFrEF
• Left ventricular end-systolic volume index measured by
cardiac magnetic resonance imaging as mL/m2
• AHF and AMI
• change of NT-proBNP levels to week 26
• de Novo or Decompensated Chronic HF
• time to death, number of heart failure events (HFEs), time to
first HFE, change in KCCQ-CSS from baseline after 90 days

NCT03030222

EMPA Acute Heart Failure
EMPA-TROPISM
EMPAG-HF
EMPA-VISION
ELSI
EMPEROR-Preserved
ERA-HF
SUGAR
EMMY
A Study to Test the Effect of Empagliflozin in
Patients Who Are in Hospital for Acute Heart
Failure

NCT03554200
NCT 03,485,222
NCT04049045
NCT03332212
NCT03128529
NCT03057951
NCT03271879
NCT03485092
NCT03087773
NCT04157751

CV cardiovascular, HF heart failure, EF ejection fraction, HFrEF HF with reduced EF, HFpEF HF with preserved EF, AMI acute myocardial
infarction, EMBRACE-HF Empagliflozin Impact on Hemodynamics in Patients With Heart Failure, ELSI Analysing the Effect of Empagliflozin
on Reduction of Tissue Sodium Content in Patients With Chronic Heart Failure, EMPAG-HF Effects of Empagliflozin on Diuresis and Renal
Function in Patients With Acute Decompensated Heart Failure, EMPEROR- Preserved EMPagliflozin outcomE tRial in Patients With chrOnic
heaRt Failure With Preserved Ejection Fraction, EMPA-VISION A Randomised, Double-blind, Placebo-controlled, Mechanistic Cardiac Magnetic Resonance Study to Investigate the Effects of Empagliflozin Treatment on Cardiac Physiology and Metabolism in Patients With Heart
Failure, ERA-HF Empagliflozin Versus Placebo on the Rate of Arrhythmic Events in Heart Failure Patients, SUGAR Studies of Empagliflozin
and Its Cardiovascular, Renal and Metabolic Effects, EMMY Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in
Patients With Acute MYocardial Infarction, EMPA-TROPISM Are the “Cardiac Benefits” of Empagliflozin Independent of Its Hypoglycemic
Activity? (ATRU-4)

SGLT2 inhibitors have the potential to change the paradigm in HF with/without T2DM patients, and evidence is
most eagerly expected for acute HF setting. The known
diuretic effect and other unknown effects could also be of
significant value in acute HF. There is evidence that urinary
output could be increased with empagliflozin [72], which
could potentially be of benefit in hospitalized HF patients
and/or for overcoming diuretic resistance. Empagliflozin is
associated with a lower risk of post-acute HF rehospitalization and mortality [73]. The ability of empagliflozin and
dapagliflozin to lower HF hospitalizations following acute
myocardial infarction will be further explored in the EMMY
trial [74] and in the DAPA-MI trial respectively (which was
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recently announced by the sponsoring company: https://
www.astrazeneca.com/media-centre/press-releases/2020/
farxiga-granted-fast-track-designation-in-the-us-for-heart-
failure-following-acute-myocardial-infarction-leveraging-
an-innovative-registry-based-trial-design.html).
Another question is whether SGLT2i have an additive
effect on top of angiotensin–neprilysin inhibitors, as the rate
of use for this class in the already published studies was
rather low (no more than 10% in DAPA-HF). The effect on
vulnerable populations (including the very elderly and the
black) is also less known.
HFpEF is another area of profound interest, lacking any
specific therapies; this is being currently investigated in
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Table 7  Active clinical trials recruiting or not using dapagliflozin in HF
Trial name

Trial design: population and primary objective

ClinicalTrials.gov Identifier:

PRESERVED-HF

• Chronic HFpEF
• Change from baseline in NTproBNP at 6 and 12 weeks
• Chronic HFrEF
• Proportion of patients with a ≥ 5pts increase in KCCQ
• Acute decompensated HD
• Composite number of hospital admissions, emergency
department visits, urgent clinic visits for Heart Failure
(HF) and death after admission
• Chronic HFpEF
• CV death and HF events
• HFrEF
• Change from baseline in 6 min walking distance
• HFpEF
• Change from baseline in 6 min walking distance
• Acute decompensated HF
• Cumulative change in weight (kilograms)
• HFrEF
• Changes in VO2 at baseline, 30 and 90 days
• HF NYHA class I-II
• Change in urinary osmolyte concentration
• HF NYHA class II-III and T2DM
• Change in LV end systolic volume or end diastolic volume
• HFrEF
• Change in myocardial perfusion reserve index
• HFpEF nad T2DM
• Time to first hospitalization for HF

NCT03030235

DEFINE-HF
Dapagliflozin HF Readmission

DELIVER
DETERMINE- Reduced
DETERMINE- Preserved
DICTATE-AHF
DAPA-VO2
DAPA-Shuttle1
REFORM
SGLTi
Effect of dapagliflozin plus low dose pioglitazone
on hospitalization rate in patients with HF and
HFpEF

NCT02653482
NCT04249778

NCT03619213
NCT03877237
NCT03877224
NCT04298229
NCT04197635
NCT04080518 [42]
NCT02397421
NCT04200586
NCT03794518

HF heart failure, EF ejection fraction, HFrEF HF with reduced ejection fraction, HFpEF HF with preserved ejection fraction, VO2 peak oxygen
consumption, PRESERVED-HF Dapagliflozin in PRESERVED Ejection Fraction Heart Failure, DEFINE-HF Dapagliflozin Effect on Symptoms
and Biomarkers in Patients With Heart Failure, DELIVER Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection
Fraction Heart Failure, DETERMINE- Reduced/Preserved Dapagliflozin Effect on Exercise Capacity Using a 6-min Walk Test in Patients With
Heart Failure With Reduced/Preserved Ejection Fraction, DICTATE-AHF Efficacy and Safety of Dapagliflozin in Acute Heart Failure, DAPAVO2 Short-term Effects of Dapagliflozin on Peak VO2 in HFrEF, DAPA-Shuttle1 Hepato-renal Regulation of Water Conservation in Heart Failure Patients With SGLT-2 Inhibitor Treatment, REFORM Safety and Effectiveness of SGLT-2 Inhibitors in Patients With Heart Failure and
Diabetes, SGLTi The Effects of SGLTi on Diabetic Cardiomyopathy

several trials, including the EMPEROR-preserved, whose
results are expected in 2021. The ongoing DELIVER study
[75] is evaluating the use of dapagliflozin specifically in this
population as well.
Among the ongoing studies with dapagliflozin, the
DAPPER [76] is an exploratory multicenter, randomized,

open-labelled study, designed to evaluate whether dapagliflozin decreases albuminuria in T2DM patients with CHF
and exerts cardioprotective effects.
Tables 6, 7, and 8 go through ongoing trials using gliflozins specifically in HF populations.

Table 8  Active clinical
trials recruiting or not using
Canagliflozin in HF

Trial name

Trial design: population and primary objective

ClinicalTrials.
gov Identifier:

CHIEF-HF

• Chronic HFp/rEF
• Change from baseline in KCCQ-TSS
• Chronic HFrEF and T2DM poorly controlled
• Change in VO2 at 12 weeks

NCT04252287

Treatment of Diabetes in Patients
With Systolic Heart Failure

NCT02920918

HF heart failure, EF ejection fraction, HFrEF HF with reduced ejection fraction, HFpEF HF with preserved ejection fraction, VO2 peak oxygen consumption, KCCQ-TSS Kansas City Cardiomyopathy Questionnaire, CHIEF-HF A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional
Status in Heart Failure
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Conclusions
HF is a highly debilitating condition affecting millions of
individuals worldwide, with a high rate of rehospitalization
and death and a poor prognosis. Several studies highlighted
the important role of gliflozins, a new class of blood glucose
lowering drugs, on cardiac remodelling, through improvements of both systolic and diastolic function, with positive
effects on renal function and cardiovascular death, even in
non-diabetic individuals. There are encouraging data on the
beneficial effect of this class of drugs, in both HFrEF and
HFpEF patients, with low incidence of adverse effects, so
that routinely introducing these drugs in daily clinical practice is increasingly considered. However, we have to wait for
the results of the ongoing studies, in order to better understand what patients, what dosages, and what associated drug
classes could ensure best results.
Abbreviations Ca2+: Calcium; CI: Confidence interval; FDA: US
Food and Drug Administration; GFR: Glomerular filtration rate;
GLP: Glucagon-like peptide; HF: Heart failure; HR: Hazard ratio;
Na+: Sodium; NHE: Sodium/hydrogen exchanger; RAAS: Renin–
angiotensin–aldosterone system; SGLT: Sodium-glucose co-transporter;
SGLT2i: Sodium-glucose co-transporter 2 inhibitor; T1DM: Type 1
diabetes mellitus; T2DM: Type 2 diabetes mellitus
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